What Counts as Prescription Drug Management in CPT 2027 E/M Coding?

Written by Jessica Miller · Published 14 November 2026 · Last reviewed 14 November 2026

Reviewed by: Jessica Miller, MHA, CPC, CPC-I, Head of Coding Operations

From January 1, 2027, CPT defines prescription drug management as drug therapy actively evaluated or directed with clinical judgment. An over-the-counter drug may reach moderate or high risk when it needs that judgment, and managing several drugs together may be high risk. Some Medicare contractor pages still say otherwise.

The panel action comes from the AMA CPT Editorial Panel Summary of Panel Actions, May 2026 , and the effective date from the AMA announcement releasing the CPT 2027 code set . Contractor wording comes from the FCSO article , the Noridian JF Part B Q&A and the WPS guide . We checked each page on 13 November 2026.

What is prescription drug management in E/M medical decision making?

Prescription drug management is an example in the risk element of medical decision making (MDM), the element that rates the risk of complications, morbidity or mortality from patient management. The MDM table lists it as a moderate-risk example, and CodingIntel notes it has been in that grid from the beginning. Until 2027, the CPT book gave it no definition of its own.

CPT 2027 adds one. As reported by CodingIntel and Part B News , the definition covers drug therapy the clinician actively evaluates or directs as part of the plan of care. That includes starting, continuing, changing, stopping or considering a prescription medicine, when the action calls for clinical judgment about effectiveness, safety or monitoring. Part B News quotes the risk sentence: "The level of risk is determined by the patient's clinical factors and the medication's potential for harm."

The AMA panel summary confirms the panel accepted a "revision to E/M guidelines to clarify prescription drug management risk." It does not reprint the text, and the AMA notes that exact wording is final only at publication. Confirm the sentences in your CPT 2027 Professional Edition before you train on them.

What changed in CPT 2027 for OTC drugs, multiple medications and chronic illness?

Four changes affect leveling. Each one depends on what the note says about the clinician's reasoning.

Over-the-counter drugs may reach moderate or high risk

Per CodingIntel and Part B News, an OTC medication may represent moderate or high risk when its use calls for the same clinical judgment as prescription drug management, based on patient-specific factors, dosage or potential adverse effects. The condition carries the weight. An OTC drug named in the plan does not qualify on its own.

Managing several medications may be high risk

The definition adds that managing multiple medications together may constitute high risk, even when no single drug would be. CodingIntel calls this sentence the new part of the definition. The word is "may." The note has to show the combined risk the clinician weighed, such as an interaction or a monitoring need.

Keep this apart from drug therapy requiring intensive monitoring for toxicity, which remains its own high-risk example. FCSO describes that monitoring as checking for adverse effects rather than therapeutic effect, and says history or examination alone does not count.

A parenteral controlled substance is not high risk by default

CodingIntel reports a new sentence saying a parenteral controlled substance does not automatically constitute high risk, and that the overall clinical context should set the risk. (CodingIntel's page spells the word "parental.")

Chronic illness with exacerbation now stresses intent to manage

The stable chronic illness definition stays the same. CodingIntel reports that some text moved into the definition of a chronic illness with exacerbation, progression or side effects of treatment, which now stresses intent to manage: "The intent is to control progression, provide additional supportive care, or manage side effects." CodingIntel calls it a small wording change, and Part B News calls it an expanded definition. CodingIntel's reading is that a worsening condition with no intervention or intent to manage may not count as an exacerbation.

CPT 2027 also adds a documentation sentence to the risk section. CodingIntel quotes it: documentation "should reasonably reflect the rationale for the clinical decision." CodingIntel expects auditors and reviewers to look for more detail on patient-specific factors.

Why the CPT and contractor gap matters for physician groups and RCM firms

From January 1, your coders will level visits under a CPT definition that some contractor education, posted before the change takes effect, reads the other way. The FCSO article dated September 23, 2026 states: "Over the counter (OTC) medications do not qualify as prescription drug management." It adds that managing prescription drugs alongside an OTC drug "may support prescription drug management when clinically appropriate." Its reference list cites AMA material from 2021 and 2023, not CPT 2027.

Noridian's JF Part B Q&A says "an order for an over the counter (OTC) drug does not count as prescription drug management," though managing prescription drugs while adding an OTC drug would. A separate Noridian article says Noridian follows AMA E/M guidelines when CMS has no separate policy, and quotes AMA guidance that risk includes medicine management, "prescription or OTC." WPS sits closest to CPT 2027. Its guide, updated November 3, 2026, says prescription drug management "can include both prescription only and over-the-counter medication prescribed."

For a physician group, a health-system professional-fee team or an RCM firm coding for clients in several MAC regions, that split creates three problems:

• Leveling drift. Two coders reading the same note can choose different risk levels, depending on whether they follow the CPT book or a contractor page.
• Review exposure. A moderate- or high-risk visit that leans on an OTC drug or on combined management is the visit a reviewer may read under older guidance. No CMS or contractor statement says it will deny or downcode on this basis, so treat it as a review risk to manage, not a forecast.
• Commercial payer variation. Plans that reduce E/M levels by algorithm will see these visits too. Our guide to detecting and appealing payer downcoding on E/M claims covers how to spot that on remits, and our post on payer-specific coding requirements for RCM teams covers keeping client rules straight.

We found no CMS statement on whether Medicare reviewers adopt the CPT 2027 definition. Check your MAC's E/M pages before January claims go out, and keep a dated copy of what you read.

CPT guidelines and contractor education are different sources

Coding teams often treat these as one rulebook. CPT guidelines, published by the AMA, define how to select an E/M level. A MAC education article explains how that contractor teaches providers and reviewers to read documentation. If the two diverge, your written policy should name the source coders follow for each payer and the reason.

A MAC article is also not national CMS policy. FCSO and Noridian speak for their own jurisdictions, and contractors can revise or withdraw pages. The FCSO page shows no update after September 23, 2026.

What should documentation show before January 1, 2027?

Train physicians on the note, not the level. The FCSO article lists four items documentation should identify, and they match the CPT 2027 rationale sentence:

1. The drug name and dosage.
2. The clinician's decision, such as continue, increase or discontinue.
3. The reason for the decision.
4. How the decision relates to the patient's current condition and treatment plan.

For an OTC drug or a multi-drug plan used to support moderate or high risk, add the patient-specific factor that made the judgment comparable to prescription drug management. Kidney function, an anticoagulant, a dose above the usual range and a monitoring need are common examples. For chronic illness with exacerbation, document the action that shows intent to manage, such as a dose change, an added therapy or added supportive care.

The table below is an illustrative example only. Level selection depends on all three MDM elements and on payer policy.

Before January, audit a sample of moderate- and high-risk visits that rely on medication management, and compare each note against the four items above. Our post on whether AI-assigned codes are audit defensible explains what a reviewer needs to see behind each code.

How MediCodio AI supports E/M documentation review

Your QA lead needs to see which sentence in the note supported the risk level. In MediCodio AI, every code ships with its documentation passage and the compliance rule behind it, a 100% code-level audit trail. Complete charts flow through AutoPilot for fully autonomous coding. Charts where the documentation is thin or contradictory stay in CoPilot, where certified coders review and finalize the output.

That routing does not settle a CPT versus MAC question for you. Your compliance team sets the policy, and your coders apply it. Nothing runs autonomous on day one. Everything starts in review, and the autonomous lane widens as first-pass accuracy is proven on your charts and audited by your team. Teams coding for physician groups or for RCM clients can see how AI medical coding fits an E/M workflow.

What has not changed

• An MDM level still needs 2 of 3 elements. Prescription drug management supports the risk element only.
• CodingIntel reports no 2027 edits to the data element.
• The stable chronic illness definition is unchanged.
• FCSO notes that a visit documented only as a refill, with no problem addressed, may not support prescription drug management.
• Medicare payment changes for 2027 come from a separate rule. See what changed in the CY2027 Physician Fee Schedule final rule .

Frequently asked questions

Does an over-the-counter drug count as prescription drug management in 2027?

It can. Per CodingIntel and Part B News, CPT 2027 says an OTC medication may represent moderate or high risk when its use needs the same clinical judgment as prescription drug management. Contractor pages differ: FCSO says OTC drugs do not qualify, while WPS scores a prescribed OTC drug as "Maybe" with documented risk.

When does the CPT 2027 prescription drug management definition take effect?

The AMA CPT Editorial Panel accepted the revision at its May 2026 meeting with an effective date of January 2027. The AMA states the CPT 2027 code set goes into effect on January 1. Your coders should apply the new guideline text to dates of service from January 1, 2027.

Can managing multiple medications support high-risk MDM?

It may. CPT 2027, as reported by CodingIntel, says managing multiple medications together may constitute high risk even when no single drug would be high risk. The note should state the combined risk the clinician weighed, such as an interaction or monitoring need. A level still needs two of three MDM elements.

Does Medicare follow the new CPT definition?

We found no CMS statement on the CPT 2027 definition. Contractor education varies. FCSO and the Noridian JF Part B Q&A still say an OTC drug alone does not count, while WPS updated its guide in November 2026. Check your own MAC's E/M pages before January and keep a dated copy.

Is a medication refill prescription drug management?

Not by itself. FCSO says an encounter documented solely as a refill, without a problem addressed or managed, may not support prescription drug management. WPS lists refills with documented evaluation of need as active management. The note has to show the clinician evaluated the drug, made a decision and gave a reason.

Book a Demo and we will run an accuracy check on a sample of your own charts, including E/M visits, with the documentation passage and rule behind every code. Book a Demo

Related reading: How to detect and appeal payer downcoding on E/M claims · What changed in the CY2027 Physician Fee Schedule final rule · Upcoding vs. downcoding: risks and audit triggers · MediCodio AI for physician groups

Sources

• AMA, CPT Editorial Panel Summary of Panel Actions, May 2026 .
• AMA, AMA releases CPT 2027 code set .
• CodingIntel, E/M Changes in CPT for 2027 , last revised 2 November 2026.
• Part B News, CPT 2027 refresh delivers E/M updates, MDM clarity and hundreds of new codes , 13 October 2026.
• JustCoding, New Rx drug management definition draws praise , 11 November 2026.
• First Coast Service Options, Medical Decision Making and the Impact of Prescription Drug Management , 23 September 2026.
• Noridian JF Part B, E/M Office or Other Outpatient Services Top Provider Questions with Answers .
• Noridian JF Part B, Evaluation and Management: Prescription Drug Management .
• WPS, Prescription Drug Management , updated 3 November 2026.